Objectives: It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. However, the perceived side-effects on muscle and liver reduce the general acceptance of statin drug therapy as well as compliance over the long term, which is necessary for prevention efforts to be successful. Chinese red yeast rice (CRYR) is a supplement containing lovastatin (monacolin K), eight other monacolins, pigments, tannins, and other phytochemicals. The authors previously reported on a double-blind placebo-controlled trial of CRYR supplement in 80 individuals demonstrating a significant decrease in cholesterol levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. The current study compared the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol.
INTRODUCTION

I
t is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. Statin drugs, which are competitive inhibitors of HMG-CoA reductase, lower cholesterol levels and reduce the progression of atherosclerotic lesions while also stabilizing pre-existing atheromatous plaques. The perceived side-effects on muscle and liver reduce the general acceptance of statin drug therapy as well as compliance over the long term, which are necessary for prevention efforts to be successful. 1 Surveys demonstrate that many Americans often turn to alternative herbal therapies for heart disease prevention rather than taking drugs, 2, 3 and view these as natural alternatives to drug therapy.
Chinese red yeast fermented on rice is a traditional food consumed throughout Asia. Its food value and medicinal value date back prior to its first recorded use in 800 AD. 4,5 A dietary supplement of Chinese red yeast rice (CRYR) has been prepared that contains only a selected strain of Monascus purpureus Went yeast and white rice on which it was fermented. There are a number of constituents in the supplement including pigments, fatty acids, and polyketides (monacolins). 6 The authors previously reported on a double-blinded placebo-controlled trial of this CRYR supplement in 80 individuals demonstrating a significant decrease in cholesterol levels from 250 mg/dL to 210 mg/dL over 8 weeks independent of diet. 7 The current study was designed to compare the pharmacokinetics of CRYR with lovastatin at the same bioeffective dose for lowering cholesterol to determine whether the body metabolizes complex mixtures of natural substances found in CRYR differently than lovastatin.
METHODS
Subjects
The study protocol was approved by the Ethics Committee of the University of California, Los Angeles and conducted at the General Clinical Research Unit (GCRC) of University of California, Los Angeles. Eleven (11) volunteers ages 25 to 45 year were recruited for the study. Written consent was obtained. All participants were in good health according to medical history, physical examination, electrocardiogram, and clinical laboratory measurements (serum chemistry, liver function tests, and hematology). Subjects were excluded if they were smokers, tobacco users, or taking any medication including over-the-counter medications within 14 days prior to the study.
Study design
This was an open label, randomized, crossover study with a 1-week washout period between two phases. The previous study had demonstrated that 2400 mg of CRYR is a relevant comparison dose to 20 mg of lovastatin for lowering blood cholesterol. 7 Kantola et al. 8 reported that grapefruit increased the serum levels of lovastatin (C max ) approximately 12-fold and the area under the concentration-time curve (AUC) 15-fold by inhibiting CYP3A4-mediated first-pass metabolism in the small intestine. The present study uses the preceding method to increase the detectable levels of monacolins.
The subjects were given 200 mL of double-strength grapefruit juice (Minute Maid frozen concentrated grapefruit juice, 12 fluid ounces (355 mL), Coca-Cola Foods, Houston, TX) three times per day (at 7 AM, noon, and 8 PM) for 2 days. On day 3, the subjects reported to the GCRC at 7:30 AM after fasting from 11 PM the previous day. A caffeine-free standardized breakfast was served at 7:45 AM and either 20 mg of lovastatin or 2400 mg of Chinese red yeast rice was given with 200 mL of double-strength grapefruit juice at 8 AM. Standardized lunch and dinner were served at noon and 5 pm. The subjects returned to the GCRC the next morning to have their blood last drawn at 8 AM.
Sample collection
On the day of administration of lovastatin or CRYR, a forearm vein of each subject was cannulated with a plastic cannula and kept patent with a heparin flush. Blood samples were obtained at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after taking lovastatin or taking CRYR. Whole blood was centrifuged immediately and plasma transferred to plastic tubes and frozen at Ϫ80°C until assay. Each C8 SPE cartridge was preconditioned with methanol (2 ϫ 1 mL) and water (2 ϫ 1 mL). Each plasma sample (400 L) was loaded onto the cartridge and allowed to freeflow by gravity. Each cartridge was then eluted with consecutive aliquots of 1 mL water, 1 mL 5% formic acid, and then 1 mL of water. The cartridge was allowed to drip dry, left to stand for 1 minute, then eluted with 1 mL methanol: water (7:3 v/v) solution, and finally with 1 mL of acetonitrile. The combined acetonitrile eluates were evaporated to dryness in vacuo at low temperature, reconstituted in the HPLC mobile phase (100 L), vortexed for 1 minute, and injected onto the LC column for LC-MS analyses.
Methodology for determination of monacolin K (lovastatin) and lovastatin hydroxy-acid in human plasma
Plasma calibration standards of lovastatin and its hydroxy-acid were prepared by spiking control human plasma with known concentrations of working solutions of the standards. Samples were processed according to the extraction procedure and injected on to the HPLC-MS. Concentrations were determined from the peak area by using the equation for linear regression obtained from the calibration curve. The A B C calibration curve was linear (R 2 ϭ 0.9954 for lovastatin and 0.9927 for lovastatin hydroxy-acid, respectively) over the concentration range from 0.1 to 100 ng/mL. The lower level of quantitation (LOQ) established from the calibration curve by LCMS was 0.1 ng/mL based on 400 L of plasma. Simvastatin was used as an internal standard as previously reported. 9 
Statistical analysis
The pharmacokinetic parameters, peak plasma concentration (C max ), time to peak plasma concentration (T max ), and time for appearance of the drug in plasma were obtained by observation. The AUC from 0 to 24 hours after dosing was calculated by the linear trapezoidal rule. Elimination half-life (t 1/2 ) was estimated by 0.693/, where is the absolute value of the slope of a least-square linear regression of plasma drug concentration (in natural logarithm scale) over time at the terminal phase.
The pharmacokinetic parameters of lovastatin and lovastatin hydroxy-acid were tabulated using mean Ϯ SEM for taking lovastatin and CRYR, respectively. This was a 2-by-2 crossover study with 7-day washout period. No carryover effect was identified, and no significant period and sequence effects were found; therefore, signed rank test was used to compare the pharmacokinetic parameters for Lovastatin versus CRYR.
All tests used were two sided with a significance level of 0.05. Statistical software SAS was used to carry out the analysis.
RESULTS
Characterization of the constituents of CRYR
This botanical dietary supplement consists mainly of rice, and by-products of fermentation. The main groups of constituents are shown in Table 1 . Clearly the most abundant ingredient is starch, constituting over 73% of the bulk. The protein content is 6%. The other ingredients are found in much less quantity. Trace elements were analyzed by atomic absorption spectroscopy. Magnesium is the most abundant metal with 1094 g/g of rice.
The typical HPLC trace for the monacolin mixture as found in CRYR is shown in Figure 1 and the Liquid Chromatography-Mass Spectrometry (LC-MS) traces of monacolin K, monacolin K hydroxyl-acid, and simvastatin standards are shown in Figures 2A-C , respectively. Figure 3 shows the LC-MS trace of a plasma sample obtained from a human subject with simvastatin added as internal standard where monacolin K and monacolin K hydroxy-acid were detected. There is 1.23 mg of monacolin K in every capsule by assay of manufacture and 1.15 mg by HPLC analyses under the same conditions.
Pharmacokinetics
The mean values and pharmacokinetics for lovastatin and CRYR are summarized in Table 2 and the mean plasma concentration versus time profiles for monacolin K and monacolin K hydroxy-acid are shown in Figures 4A,B , respectively. Monacolin K was detected in plasma 30 minutes after ingestion of either lovastatin or CRYR. The peak concentration reached at approximately 3 hours. The C max and AUC of lovastatin are 22.42 ng/mL, and 80.47 higher than CRYR with p value of 0.001 and 0.002, respectively. The dose-normalized C max and AUC of lovastatin are 0.89 ϩ 0.22 ng/mL, and 3.41 ϩ 0.99 higher than CRYR with p value of 0.001 and 0.002, respectively.
Monacolin K hydroxy-acid was detected 30 minutes after taking lovastatin or CRYR but peaked at 4 hours, 1 hour later than when monacolin K peaked. The T max for lovastatin and CRYR hydroxy-acids were similar (p ϭ 1.00, signed rank test). The C max for loavstatin hydroxy-acid is 36.63 ng/mL higher than the C max of CRYR hydroxy-acid (p ϭ 0.001, signed rank test). The AUC of lovastatin hydroxy-acid is 258.5 larger than that of CRYR (p ϭ 0.001). After normalization for dose, the AUC of lovastatin is still 7.21 larger than that of CRYR (p ϭ 0.001).
The individual sample for minor monacolins were not detectable by LC-MS/MS. However, the pooled plasma samples collected from three subjects showed the presence of minor monacolins reported to be present in CRYR. 10 
DISCUSSION
In 1979, Endo 11 reported that a strain of Monascus yeast naturally produces a substance that inhibits cholesterol synthesis, which he named monacolin K, as well as a family of eight monacolin-related substances with the ability to inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. In addition to the inhibitors of HMG-CoA reductase, red yeast rice has been found to contain sterols (␤-sitosterol, campesterol, and stigmasterol), tannins, polyketide pigments, sapogenin, isoflavones and isoflavone glycosides, and monounsaturated fatty acids. 11, 12 CRYR has been shown to lower cholesterol in animals fed diets designed to induce hypercholesterolemia. 13, 14 In a double-blind placebo-controlled and diet-controlled study, CRYR was demonstrated to lower serum cholesterol by 23% in 40 hypercholesterolemic patients compared to 40 patients 
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given placebo. 7 The monacolins in CRYR and drug statins are competitive inhibitors of HMG CoA reductase, the regulatory enzyme of cholesterol synthesis. 15 The current study showed that the quantity of monacolin K contained in CRYR is much lower and is inadequate to explain the magnitude of cholesterol lowering observed in the previous study. The 2400 mg CRYR used in this study contains only 4.6 mg, 23% of monacolin K of 20 mg lovastatin. The findings of this study demonstrated that the plasma concentrations of monacolin K and its hydroxy-acid form are much higher after ingestion of lovastatin than CRYR. The mixture of monacolins and other substances present in the red yeast rice may have some inhibitory effect on cholesterol biosynthesis. Pooled plasma collected from three subjects showed the presence of additional minor monacolins that are known to be present in red yeast rice. 10 Various synthetic statins have different degrees of biologic activity, and it is possible that the family of monacolins in CRYR may have a different profile of cellular or molecular actions. In the current study the monacolin K to monacolin K hydroxy-acid ratio was 1.72 for lovastatin and 3.48 for CRYR, which further suggests possible different metabolism. At 72 hours after administration, approximately 83% of lovastatin was excreted in stool and 10% in urine. 16 Similar studies of the bioavailability and bioactivity of CRYR monacolins were not performed previously but would increase the understanding of the metabolism of this botanical dietary supplement.
Whereas the proprietary product used in this study was demonstrated to lower cholesterol levels significantly in clinical trials, other products being sold as CRYR dietary supplements have not undergone similar evaluation. Nine proprietary CRYR supplements were analyzed and it was found that the total monacolin content can vary from 0% to 0.58% w/w, only 1/9 preparations had the full complement of 10 monacolin compounds. 17 Most of the pharmacokinetic data reported for statins in the literature have been generated using the HMG-CoA reductase assay to determine total and active inhibitors of HMG-CoA reductase. 18 Although this enzymatic method can determine the entire latent and active drug and metabolites of lovastatin, it is not chemically specific. In contrast, the LC-MS/MS method used for determining plasma drug concentrations in this study is more sensitive and specific. 9, 19 By using LC-MS/MS methodology, lovastatin was detectable a half hour after the 20-mg dose was administered.
The benefits of statin drugs on the primary prevention of heart disease 20, 21 and in the secondary prevention of recurrent heart disease 22, 23 have been shown in several large, prospective clinical trials. These studies have increased interest in the prophylactic use of statins for heart disease prevention for individuals with hypercholesterolemia. The National Cholesterol Education Program (NCEP) guidelines were updated recently about pharmacologic intervention. NCEP is now advocating more aggressive therapy for patients with high and moderate risks. 24 Although it is acknowledged that side-effects with statins are rare, there are data indicating that some statins may cause liver function abnormalities and, under certain circumstances, rhabdomyolysis in a doserelated fashion. 25 Combined use of different statins in lower doses may decrease the incidence of side-effects.
CONCLUSIONS
In summary this study demonstrated significantly lower serum monacolin K level for CRYR compared to equivalent cholesterol-lowering dose of lovastatin. CRYR may serve as a safe and effective natural alternative for people with modest elevation of cholesterol. The effect of red yeast rice on the cholesterol concentration is not caused by monacolin K alone but the combination of monacolin K and other monacolins, substances in the red yeast rice supplement.
